DK3801524T3 - Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation - Google Patents
Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutationInfo
- Publication number
- DK3801524T3 DK3801524T3 DK19810149.5T DK19810149T DK3801524T3 DK 3801524 T3 DK3801524 T3 DK 3801524T3 DK 19810149 T DK19810149 T DK 19810149T DK 3801524 T3 DK3801524 T3 DK 3801524T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical composition
- treating cancer
- cancer associated
- egfr mutation
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679619P | 2018-06-01 | 2018-06-01 | |
| PCT/US2019/034726 WO2019232257A1 (en) | 2018-06-01 | 2019-05-30 | Composition and method of treating cancer associated with egfr mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3801524T3 true DK3801524T3 (da) | 2026-02-02 |
Family
ID=68696755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19810149.5T DK3801524T3 (da) | 2018-06-01 | 2019-05-30 | Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210161888A1 (https=) |
| EP (1) | EP3801524B1 (https=) |
| JP (1) | JP7500438B2 (https=) |
| KR (1) | KR102790127B1 (https=) |
| CN (1) | CN112543636B (https=) |
| AU (1) | AU2019278886B2 (https=) |
| CA (1) | CA3101612A1 (https=) |
| DK (1) | DK3801524T3 (https=) |
| ES (1) | ES3060133T3 (https=) |
| MX (1) | MX420412B (https=) |
| WO (1) | WO2019232257A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| AU2022357570A1 (en) * | 2021-10-03 | 2024-04-11 | Systimmune, Inc. | Methods of treating cancer and the pharmaceutical compositions thereof |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| EP4719416A1 (en) * | 2023-06-02 | 2026-04-08 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0313363A (pt) * | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| US20110160159A1 (en) * | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| AU2016219204B2 (en) * | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| MX383691B (es) * | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| AU2018236168B2 (en) * | 2017-03-13 | 2024-02-29 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
-
2019
- 2019-05-30 ES ES19810149T patent/ES3060133T3/es active Active
- 2019-05-30 US US17/059,694 patent/US20210161888A1/en not_active Abandoned
- 2019-05-30 JP JP2020567029A patent/JP7500438B2/ja active Active
- 2019-05-30 KR KR1020207036949A patent/KR102790127B1/ko active Active
- 2019-05-30 CA CA3101612A patent/CA3101612A1/en active Pending
- 2019-05-30 MX MX2020012799A patent/MX420412B/es unknown
- 2019-05-30 AU AU2019278886A patent/AU2019278886B2/en active Active
- 2019-05-30 EP EP19810149.5A patent/EP3801524B1/en active Active
- 2019-05-30 CN CN201980050963.3A patent/CN112543636B/zh active Active
- 2019-05-30 WO PCT/US2019/034726 patent/WO2019232257A1/en not_active Ceased
- 2019-05-30 DK DK19810149.5T patent/DK3801524T3/da active
-
2025
- 2025-05-23 US US19/217,307 patent/US20250375440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250375440A1 (en) | 2025-12-11 |
| US20210161888A1 (en) | 2021-06-03 |
| KR102790127B1 (ko) | 2025-04-03 |
| JP2021525768A (ja) | 2021-09-27 |
| CN112543636B (zh) | 2024-03-01 |
| EP3801524A1 (en) | 2021-04-14 |
| MX420412B (es) | 2025-02-10 |
| JP7500438B2 (ja) | 2024-06-17 |
| CA3101612A1 (en) | 2019-12-05 |
| CN112543636A (zh) | 2021-03-23 |
| EP3801524B1 (en) | 2025-11-05 |
| KR20210015875A (ko) | 2021-02-10 |
| AU2019278886B2 (en) | 2025-03-20 |
| AU2019278886A1 (en) | 2020-12-24 |
| WO2019232257A1 (en) | 2019-12-05 |
| MX2020012799A (es) | 2021-03-25 |
| ES3060133T3 (en) | 2026-03-25 |
| EP3801524A4 (en) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3801524T3 (da) | Farmaceutisk sammensætning og fremgangsmåde til behandling af kræft associeret med egfr-mutation | |
| EP3838803A4 (en) | DISTRIBUTION AGENCY AND DISTRIBUTION METHOD | |
| EP3869985A4 (en) | COMPOSITION AND METHOD OF TREATMENT OF THE LUNGS | |
| DK4075992T3 (da) | Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf | |
| DK3902803T3 (da) | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK4279084T3 (da) | Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi | |
| DK3565844T3 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
| DK3386518T3 (da) | Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse | |
| DK4169491T3 (da) | Indretninger og fremgangsmåde til behandling af bruxisme | |
| DK3250210T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3810281T3 (da) | Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3519049T3 (da) | Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof | |
| DK3704227T3 (da) | Sammensætning og fremgangsmåde | |
| DK4434585T3 (da) | Forbindelser og fremgangsmåder til reduktion af snca-ekspression | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK4004022T3 (da) | Materialer og fremgangsmåder til behandling af friedreichs ataksi | |
| DK3481856T3 (da) | Materialer og metoder til behandling af smerterelaterede lidelser | |
| IL288086A (en) | Methods and materials for treating cancer | |
| DK3554760T3 (da) | Fremgangsmåder og apparat til formgivning af arbejdsstykker | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3496743T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler |